Skip to main content

Table 7 Multivariate analysis of risk factors for progression-free survival

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Factors Multivariate Analysis
HR 95% CI P
Male 1.364 0.613–3.035 0.447
TACE + sorafenib versus sorafenib 0.461 0.273–0.780 0.004
Age 0.995 0.976–1.014 0.581
Tumor number 1.140 0.936–1.389 0.193
Tumor diameter (cm) 1.038 0.969–1.111 0.288
No vascular invasion 0.557 0.314–0.988 0.045
Metastasis 1.334 0.834–2.133 0.229
Child-Pugh stage A 0.991 0.484–2.030 0.980
AFP < 400 ng/mL 0.695 0.437–1.106 0.125
  1. AFP Alpha-fetoprotein, CI confidence interval, HR hazard ratio